Moreover, the MET Gastric trial, in which patients with GC with MET overexpression (immunohistochemistry [IHC], 2+/3+) received onartuzumab, an anti-MET monoclonal antibody, plus FOLFOX did not demonstrate significantly improved survival [13]. This evidence concerns the gene MET and gastric cancer.